Elevance Health, Inc. $ELV Shares Sold by Diversified Trust Co

Diversified Trust Co cut its stake in Elevance Health, Inc. (NYSE:ELV) by 46.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,087 shares of the company’s stock after selling 16,839 shares during the quarter. Diversified Trust Co’s holdings in Elevance Health were worth $5,588,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ELV. Rossby Financial LCC increased its stake in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after buying an additional 44 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of Elevance Health in the fourth quarter valued at approximately $31,000. J.Safra Asset Management Corp acquired a new stake in shares of Elevance Health in the fourth quarter worth approximately $32,000. ORG Partners LLC boosted its stake in shares of Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after acquiring an additional 59 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Elevance Health during the fourth quarter worth approximately $38,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.34% of the company’s stock.

Elevance Health Stock Performance

Shares of Elevance Health stock opened at $388.77 on Friday. The business’s 50 day moving average price is $375.30 and its 200 day moving average price is $346.91. The company has a market cap of $84.43 billion, a price-to-earnings ratio of 16.54, a PEG ratio of 2.20 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $426.98.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same period in the prior year, the business earned $11.97 EPS. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts predict that Elevance Health, Inc. will post 26.93 EPS for the current year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. Elevance Health’s dividend payout ratio is currently 29.26%.

Analyst Ratings Changes

A number of brokerages have weighed in on ELV. Guggenheim raised their price objective on Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a report on Friday, April 24th. Jefferies Financial Group dropped their target price on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a report on Monday, April 20th. Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. Bank of America raised their price target on shares of Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research note on Thursday, June 4th. Finally, Barclays boosted their price target on shares of Elevance Health from $408.00 to $480.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Fourteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $416.11.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.